Chronic Lymphocytic Leukemia

• Clonal B-cell proliferation with impaired apoptosis: CLL arises from a single malignant B lymphocyte clone that expands through a multi-hit process involving genetic and epigenetic aberrations. The hallmark is acquisition of antiapoptotic mechanisms—primarily through upregulation of BCL2 and MCL1 proteins—that allow leukemic cells to evade normal programmed cell death pathways despite accumulating DNA damage. This defect in apoptosis is the fundamental reason cells persist in blood and tissues rather than being cleared. The leukemic B cells demonstrate increased expression of anti-apoptotic genes through both chromosomal translocations (del(14;18) involving BCL2, though less common in CLL than lymphoma) and constitutive activation of survival signaling cascades. The transformed cells are usually CD5+ B lymphocytes, which represents clonal expansion of a normally minor B-cell subset; this CD5 co-expression is diagnostically useful and reflects disruption of normal B-cell development and tolerance mechanisms.

• B-cell receptor (BCR) and microenvironment signaling: CLL cells retain functional B-cell receptor signaling capacity, though paradoxically most cells display low surface immunoglobulin expression. The BCR ligand engagement leads to phosphorylation of Src-family kinases (LYN, BLK) and spleen tyrosine kinase (SYK), which recruit and activate BTK (Bruton tyrosine kinase) and phospholipase C-gamma. This BCR signaling cascade activates downstream PI3K/AKT/mTOR and NF-κB pathways, promoting cell survival and proliferation. The tissue microenvironment is critical to CLL pathogenesis—leukemic cells home preferentially to lymphoid tissues and bone marrow niches where they receive survival signals from stromal cells, nurse cells, and T cells through CD40-CD40L interaction, BAFF receptor signaling, and IL-6 production. This explains why CLL cells may be relatively quiescent in peripheral blood yet proliferate actively in tissues; removing cells from the microenvironment (as occurs with ex vivo culture) rapidly triggers apoptosis. BTK inhibitors mechanistically interrupt both BCR signaling and integrin-mediated adhesion to the microenvironment, accounting for their remarkable clinical efficacy.

• Chromosomal abnormalities and molecular subgroups: CLL demonstrates heterogeneous karyotypic abnormalities detectable by fluorescence in situ hybridization (FISH), each carrying distinct prognostic implications. Deletion 13q14 (del(13q)), the most common abnormality found in ~55% of cases, involves loss of the miR-15a/miR-16-1 cluster and is associated with relatively favorable prognosis and longer median survival (>10 years). Trisomy 12 (~15% of cases) confers intermediate prognosis. Deletion 11q (del(11q), ~10% of cases) involves the ATM gene and is associated with more aggressive disease, younger age at presentation, and intermediate survival (~7 years). Deletion 17p (del(17p), ~5-10% of cases) represents loss of TP53 and is the most adverse prognostic marker, predicting rapid progression, short survival (~3-4 years without modern therapy), and resistance to conventional chemotherapy—this finding mandates alternative approaches such as BTK inhibitors or venetoclax. TP53 mutation (present in ~10-15% of CLL cases) carries similarly poor prognosis independent of del(17p). The IGHV mutation status reflects whether the leukemic clone arose from antigen-experienced or naive B cells; unmutated IGHV (<98% homology to germline) indicates presumed derivation from naive cells and predicts aggressive disease with shorter survival, while mutated IGHV (≥98% homology) suggests antigen selection and more indolent course. Recent genomic studies have identified recurrent mutations in SF3B1, TP53, NOTCH1, and MYD88, further refining prognostic models and emerging as targets for therapy.

• Immune dysfunction and infection: Beyond cell-autonomous properties, CLL induces profound immune dysfunction that contributes to morbidity. Leukemic B cells produce minimal functional antibodies despite clonal expansion, leaving patients with hypogammaglobulinemia and impaired humoral immunity despite elevated total immunoglobulin levels. CLL patients develop T-cell exhaustion and CD4+ T-cell lymphopenia through unknown mechanisms involving PD-1 upregulation and reduced IL-2 production. Complement-mediated immune clearance is compromised. These defects explain the markedly increased susceptibility to infections with encapsulated bacteria (S. pneumoniae, H. influenzae), atypical organisms (Mycobacterium avium complex, Listeria, Cryptococcus), viruses (CMV, VZV), and fungi—cumulative infection risk becomes substantial with disease duration and immunosuppressive therapy.

• Tumor burden and organ infiltration: CLL manifests as progressive lymphocytic infiltration of lymphoid organs and marrow. Leukemic lymphocytes accumulate preferentially in bone marrow (causing marrow infiltration and cytopenias), spleen (causing splenomegaly), and lymph nodes (causing lymphadenopathy) through homing mechanisms mediated by chemokine receptors (CCR7, CXCR4) and integrins. Progressive marrow replacement directly causes anemia, thrombocytopenia, and leukopenia despite elevated circulating lymphocytes, reflecting impaired normal hematopoiesis. The bone marrow microenvironment actively nurtures leukemic cells while simultaneously inhibiting normal myelopoiesis through unknown mechanisms, possibly involving abnormal osteoclast and osteoblast activity.

• Age and genetic predisposition: CLL is fundamentally a disease of aging, with incidence rising exponentially after age 60, reaching >15 per 100,000 person-years in those ≥75 years. This age association reflects time required for accumulation of multiple genetic and epigenetic hits. Familial CLL occurs in 5-10% of cases, with increased incidence among relatives of affected individuals suggesting underlying genetic susceptibility; genome-wide association studies have identified common SNPs in FAT4, DLEU7, and other loci associated with increased CLL risk. Twin studies suggest heritability of ~40-50%. Male predominance (2:1) exists without clear mechanistic explanation, though sex hormone influences on B-cell development and immune aging may contribute. Ethnicity influences disease presentation, with lower incidence in Asian populations and higher incidence in Caucasians and Ashkenazi Jews.

• Chronic antigenic stimulation and autoimmunity: Some epidemiologic data suggest associations between CLL and prior infections (hepatitis C, Borrelia, Chlamydia psittaci) or chronic antigenic stimulation, though causality remains unproven. Patients with CLL have increased prevalence of autoimmune manifestations, particularly autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP), occurring in 4-10% and 2-5% of CLL patients respectively. Whether autoimmunity predisposes to CLL or arises secondary to immune dysregulation induced by CLL remains unclear; likely CLL cells producing anti-self antibodies or impaired T-regulatory function allows emergence of autoreactive B-cell clones.

• Occupational and environmental exposures: Occupational exposure to organic solvents, pesticides, and herbicides (particularly Agent Orange) has shown associations with increased CLL risk in some case-control studies, though mechanistic links and causality remain debated. Smoking and alcohol use do not show consistent associations. Ionizing radiation exposure increases CLL risk, as demonstrated in atomic bomb survivors and early medical radiation workers, though the magnitude of risk is less than for acute leukemias. No clear evidence links viral infections (including HIV, HTLV-1, or EBV) to CLL pathogenesis, distinguishing it from other lymphoproliferative malignancies.

• Chronic stimulation of clonal B-cell expansion: In rare instances, monoclonal B-cell lymphocytosis (MBL)—clonally expanded B cells <5,000/μL with phenotype identical to CLL but without cytopenias or organomegaly—represents a precursor condition progressing to CLL at a rate of 1-2% per year. MBL occurs in 3-5% of healthy adults and increases with age; its presence does not mandate treatment but represents an identifiable "at-risk" state.

• Asymptomatic disease with incidental lymphocytosis: Approximately 25-50% of CLL patients are asymptomatic at diagnosis, with disease identified incidentally on routine laboratory examination revealing lymphocytosis. These patients may have no constitutional symptoms, lymphadenopathy, or organomegaly on examination. This asymptomatic presentation reflects the indolent nature of early-stage disease and explains why CLL is increasingly detected in younger patients through routine blood work, raising questions about the appropriate management of asymptomatic early-stage CLL.

• B symptoms and constitutional manifestations: Patients with more advanced CLL may present with fever, night sweats, and unintentional weight loss (B symptoms) indicating higher disease burden and more aggressive biology. These symptoms occur more frequently in patients with del(17p), TP53 mutations, or unmutated IGHV status and signal need for more intensive investigation and treatment consideration. Fatigue and malaise are common, often attributable to anemia, cytokine production by leukemic cells (TNF-α, IL-6), or concurrent infections. Patients may report dyspnea on exertion or palpitations reflecting anemia severity.

• Lymphadenopathy and organomegaly: Painless lymphadenopathy is present in 25-80% of patients at diagnosis, typically affecting cervical, axillary, and inguinal nodal chains with rubbery, mobile, non-tender quality. Splenomegaly occurs in 25-55% of cases and may be clinically significant, occasionally causing splenic infarction or rupture with severe trauma. Hepatomegaly occurs in ~10-20% but is typically mild without associated liver dysfunction. The degree of organomegaly and lymphadenopathy generally correlates with disease burden and prognosis.

• Cytopenias and marrow involvement: Progressive anemia develops in 10-20% of newly diagnosed CLL patients and becomes increasingly common with advancing disease. Thrombocytopenia (platelets <100,000/μL) occurs in 10-15% and may be immune-mediated (ITP) or secondary to marrow infiltration. Neutropenia is less common but may develop with advanced marrow involvement. These cytopenias often progress gradually but can present acutely if occurring as part of Richter transformation or when combined with autoimmune cytopenias. Bleeding manifestations (mucosal bleeding, petechiae, easy bruising) indicate significant thrombocytopenia.

• Autoimmune complications: Autoimmune hemolytic anemia (AIHA) complicates 4-10% of CLL cases and presents with jaundice, dark urine, dyspnea, and hyperbilirubinemia with positive direct Coombs test (predominantly IgG-mediated, sometimes warm-reactive). Immune thrombocytopenia (ITP) presents with mucosal bleeding, petechiae, purpura, and severely reduced platelet counts despite adequate megakaryocytes on marrow examination. Pure red cell aplasia (PRCA) and Evans syndrome (combined AIHA and ITP) are less common but clinically significant. These autoimmune manifestations may occur at diagnosis or develop during disease course; response to therapy may be discordant from response of CLL itself.

• Infections: Infection is the most common cause of morbidity and mortality in CLL patients. Bacterial infections (pneumonia, sinusitis, urinary tract infection, meningitis) involving encapsulated organisms dominate early disease. Opportunistic infections (CMV, PCP, Cryptococcus, MAC, Listeria) become increasingly prevalent as disease advances and immune function deteriorates or with treatment. Viral reactivation, particularly cytomegalovirus (CMV), can occur spontaneously or be triggered by treatment. Some patients present acutely with infection as the initial manifestation of CLL.

• Richter transformation: Occurring in 2-5% of CLL patients, Richter transformation (also called Richter syndrome) represents transformation of CLL to diffuse large B-cell lymphoma (DLBCL), presenting acutely with rapid clinical deterioration, marked elevation of LDH, enlarging lymph nodes/spleen, B symptoms (often with high fever), hypercalcemia, and performance status decline. This transformation may occur spontaneously, be triggered by infection (particularly EBV), or occasionally be induced by certain chemotherapy regimens. Prognosis of Richter transformation is poor (median survival 5-8 months) despite aggressive DLBCL-directed chemotherapy.

• Secondary malignancies: CLL patients have modestly increased risk of secondary solid malignancies (skin cancers, lung cancer), though absolute incidence remains relatively low. Risk appears partially attributable to immune dysfunction and chronic antigenic stimulation rather than direct leukemic cell transformation.

• Complete blood count with differential and peripheral blood smear: Diagnosis begins with identification of sustained absolute lymphocytosis (≥5,000 B lymphocytes/μL) persisting for ≥3 months. The white blood cell count typically ranges from 5,000 to >500,000/μL at presentation. The differential shows absolute lymphocytosis with percentage of lymphocytes often ≥50%. Peripheral blood smear examination reveals small, mature-appearing lymphocytes with scant cytoplasm and compact chromatin (described as "soccer ball" appearance due to irregular nuclear membrane); characteristic "smudge cells" (basket cells)—disrupted, nuclear fragments from fragile cells damaged during smear preparation—are pathognomonic for CLL. Anemia (hemoglobin <11 g/dL) and thrombocytopenia (platelets <100,000/μL) may be present at diagnosis or develop with advancing disease and indicate more advanced stage. Initial complete metabolic panel should assess renal function and LDH; elevated LDH (>500 IU/L) indicates higher disease burden and poorer prognosis.

• Flow cytometry immunophenotyping: Flow cytometry is the gold standard diagnostic test and is essential for confirmation and staging of CLL. CLL demonstrates a highly characteristic CD5+, CD19+, CD20+ (dim), CD23+, CD10−, FMC7−, surface immunoglobulin (dim) B-cell phenotype. The CD5+CD19+ co-expression is particularly diagnostically useful, distinguishing CLL from other B-cell lymphoproliferative disorders; CD5 is normally expressed on T cells but not B cells, making CD5+B cells the hallmark of CLL. CD19 and CD20 are B-cell markers, but CLL demonstrates characteristically dim CD20 and CD23 expression, whereas marginal zone lymphoma shows the opposite pattern (bright CD20, negative CD23). CLL shows restricted light chain expression (either κ or λ) in 95% of cases, confirming monoclonality and ruling out polyclonal B-cell activation. CD10 negativity and FMC7 negativity distinguish CLL from follicular lymphoma. The absolute CD5+CD19+ count is used for diagnostic criteria and prognosis; CLL must have ≥5,000 B lymphocytes/μL (compared to monoclonal B-cell lymphocytosis with <5,000/μL). Flow cytometry also assesses for ZAP-70 expression (>20% on CD19+ B cells suggests unmutated IGHV and

Step 1 — decide whether to treat at all

• Observation ("watch and wait"): Asymptomatic early-stage disease (Rai 0, Binet A) is monitored with serial CBC and exam. Randomized data show no survival benefit from early treatment, and the International Workshop on CLL (iwCLL) criteria endorsed by NCCN restrict therapy to active disease: progressive marrow failure (worsening anemia/thrombocytopenia), massive or symptomatic splenomegaly or lymphadenopathy, lymphocyte doubling time under ~6 months, disabling constitutional symptoms, or autoimmune cytopenia refractory to corticosteroids.
• A high WBC alone is not an indication: CLL lymphocytes are small and deformable, so leukostasis is rare — do not leukapherese a stable patient with a WBC in the hundreds of thousands.
• Pre-treatment testing: FISH for del(17p), TP53 sequencing, and IGHV mutation status must be obtained before each line of therapy, because they select the regimen.

First-line therapy (NCCN CLL/SLL guidelines)

• Covalent BTK inhibitors: acalabrutinib or zanubrutinib (second-generation, favored over ibrutinib for fewer cardiac/bleeding events) given continuously; they block BCR signaling and tissue homing.
• BCL2 inhibitor combination: venetoclax plus the anti-CD20 antibody obinutuzumab, given as fixed duration. Venetoclax requires a stepwise weekly ramp-up with hydration and allopurinol because of tumor lysis risk.
• Chemoimmunotherapy (fludarabine/cyclophosphamide/rituximab, bendamustine-rituximab) has been largely displaced by targeted agents and is reserved for select fit patients with mutated IGHV.

Escalation and definitive options

• Switch mechanism at progression: BTK inhibitor failure → venetoclax-based therapy, and vice versa; the noncovalent BTK inhibitor pirtobrutinib covers BTK C481S resistance. CD19 CAR T-cell therapy and, in young fit high-risk patients, allogeneic stem cell transplant are the only potentially curative options.
• Autoimmune cytopenias: corticosteroids (prednisone) first, then rituximab/IVIG; splenectomy is now rarely needed.

Contraindicated / avoid

• Chemoimmunotherapy in del(17p)/TP53-mutated disease — p53-independent targeted agents are required.
• Live vaccines (per ACIP, use recombinant zoster vaccine, not the live formulation); warfarin and strong CYP3A inhibitors with ibrutinib; anti-CD20 therapy without hepatitis B screening.

Disease-related

• Infection (leading cause of death): Hypogammaglobulinemia plus T-cell exhaustion impairs opsonization of encapsulated organisms. Fever with neutropenia or sepsis physiology is an emergency — blood cultures and empiric broad-spectrum antibiotics per IDSA febrile neutropenia guidance take precedence over CLL-directed workup. Recurrent sinopulmonary infection with documented hypogammaglobulinemia is the trigger to consider IVIG replacement.
• Richter transformation: Clonal evolution to diffuse large B-cell lymphoma. Signaled by rapid deterioration, high fever, asymmetric rapidly enlarging node, hypercalcemia, and an abrupt LDH surge. Best next step is excisional biopsy of the most FDG-avid node, not more flow cytometry.
• Autoimmune cytopenias: Warm IgG-mediated AIHA (spherocytes, high reticulocyte count, positive direct antiglobulin test, low haptoglobin) and ITP. A high retic count distinguishes hemolysis from marrow replacement, where the retic count is inappropriately low.
• Secondary malignancy: Immune surveillance failure raises risk of skin cancers — annual dermatologic surveillance.

Treatment-related

• Tumor lysis syndrome with venetoclax: Massive BCL2-dependent apoptosis releases intracellular contents. Emergency: hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, acute kidney injury. Prevented by dose ramp-up, hydration, and xanthine oxidase inhibition (rasburicase if urate is markedly elevated; avoid in G6PD deficiency).
• BTK inhibitor toxicity: Off-target kinase inhibition causes atrial fibrillation, hypertension, and bleeding (impaired platelet GPVI/collagen signaling) — hold before procedures; ventricular arrhythmia and sudden death are reported with ibrutinib.
• Redistribution lymphocytosis: A rising ALC after starting a BTK inhibitor reflects egress of cells from nodes as adhesion is blocked, with shrinking nodes — this is expected, not progression.
• Anti-CD20 antibodies: Infusion reactions, hepatitis B reactivation (screen HBsAg/anti-HBc; fulminant hepatitis is an emergency), and rare PML.
• Purine analogs (fludarabine): Prolonged CD4 lymphopenia requiring PJP and herpesvirus prophylaxis, AIHA, and transfusion-associated GVHD — use irradiated blood products.

• Smudge (basket) cells on smear plus absolute lymphocytosis of small mature lymphocytes in an older adult is CLL until proven otherwise; flow cytometry — not bone marrow biopsy — is the single best next step to confirm.
• The immunophenotype examiners test: CD5+ CD19+ CD23+ with dim CD20 and dim surface immunoglobulin. The classic distractor is mantle cell lymphoma, which is also CD5+ but is CD23-negative, cyclin D1-positive with t(11;14).
• del(17p)/TP53 is the answer to "which finding changes management": it predicts chemoimmunotherapy resistance, so the stem wants a BTK inhibitor or venetoclax-based regimen, never FCR.
• Asymptomatic early-stage disease is observed, no matter how impressive the WBC. Treating on lymphocyte count alone is a trap; leukostasis essentially does not occur in CLL because the cells are small and mature (contrast with AML blast crisis).
• Anemia + jaundice + high reticulocytes + positive direct Coombs in a CLL patient is warm AIHA — treat with corticosteroids, and remember the CLL itself may not need therapy yet.
• Rapidly enlarging single node, high fever, and a soaring LDH = Richter transformation to DLBCL; the next step is excisional lymph node biopsy, and prognosis is poor.
• Drug–toxicity pairs: venetoclax → tumor lysis syndrome (hence weekly ramp-up); ibrutinib → atrial fibrillation, hypertension, and bleeding; anti-CD20 antibodies → hepatitis B reactivation (screen first).
• Vaccinate but avoid live vaccines (ACIP): give inactivated influenza, pneumococcal, and recombinant zoster vaccine; responses are blunted by hypogammaglobulinemia, and recurrent infections may warrant IVIG.
• Rising lymphocyte count right after starting a BTK inhibitor with shrinking nodes is expected redistribution, not treatment failure — do not switch therapy.